GlobeNewsWire · ELDN · October 26, 2026
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗